Levels of serum trace elements in patients with Peyronie

Güneş, Mustafa; Aslan, Rahmi; Eryılmaz, Recep; Demır, Halit; Taken, Kerem

doi:10.1080/13685538.2018.1474195

Cited by 11 publications

(14 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, matrixins (MMP) require Zn 2+ ions for adequate functioning and catalytic activity. 38 , 39 Gunes et al 40 recently applied atomic absorption spectrophotometry and found significantly lower levels of the trace elements Mn, Cu, Zn, and Fe, whereas levels of Cd and Co remained unchanged in patients with PD. A zinc deficiency might contribute to the progression of fibrotic changes.…”

Section: Introductionmentioning

confidence: 99%

New insights into the pathogenesis of Peyronie's disease: A narrative review

Krakhotkin¹,

Chernylovskyi²,

Mottrie

et al. 2020

Chronic Diseases and Translational Medicine

View full text Add to dashboard Cite

Peyronie’s disease (PD) is a benign, progressive fibrotic disorder characterized by scar or plaques within the tunica albuginea (TA) of the penis. This study provides new insights into the pathogenesis of PD based on data from different studies regarding the roles of cytokines, cell signaling pathways, biochemical mechanisms, genetic factors responsible for fibrogenesis. A growing body of literature has shown that PD is a chronically impaired, localized, wound healing process within the TA and the Smith space. It is caused by the influence of different pathological stimuli, most often the effects of mechanical stress during sexual intercourse in genetically sensitive individuals with unusual anatomical TA features, imbalanced matrix metalloproteinase/tissue inhibitor of metalloproteinase (MMP/TIMP), and suppressed antioxidant systems during chronic inflammation. Other intracellular signal cascades are activated during fibrosis along with low expression levels of their negative regulators and transforming growth factor-β1 signaling. The development of multikinase agents with minimal side effects that can block several signal cell pathways would significantly improve fibrosis in PD tissues by acting on common downstream mediators.

show abstract

Section: Introductionmentioning

confidence: 99%

New insights into the pathogenesis of Peyronie's disease: A narrative review

Krakhotkin¹,

Chernylovskyi²,

Mottrie

et al. 2020

Chronic Diseases and Translational Medicine

View full text Add to dashboard Cite

show abstract

“…The average IIEF-5 score before treatment was 18.1 (10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25). This score increased to 20.2 (10-25) after treatment.…”

Section: Resultsmentioning

confidence: 97%

Intralesional Low Dose Methylprednisolone for the Treatment of Active Phase Peyronie’s Disease: A Single Center, Preliminary Prospective Non-Randomised Study

Üre

Özen

2020

Preprint

View full text Add to dashboard Cite

Aim There are few types of drugs that can be used in the active phase of Peyronie's disease. Methylprednisolone is a corticosteroid with a strong anti-inflammatory effect. In this study, we aimed to evaluate the effect of intralesional low dose methylprednisolone treatment on patients in the active phase of Peyronie's disease. Patients and Methods Forty-eight patients suffering from Peyronie's disease active phase symptoms were included in the study. Methylprednisolone was administered intralesionally for 8 weeks, once per week, at a dose of 40 mg. The injection was applied into the plaques, which causes maximum curvature. Patients were evaluated before and after treatment for plaque size, angle of curvature, and erectile dysfunction according to the International Index of Erectile Function-5 and Peyronie's Disease Questionnaire. Results The mean age of the patients was 61.1 (43-78) years. Mean duration of the symptoms was 3.4 (0-9) months. The average plaque size before treatment was 13.6 mm (7.1-16.8) and after treatment, this value decreased to 10.8 mm (4.3-14.6) (p:0.025). The average scores of Peyronie's Disease Questionnaire elements; symptom severity, penile pain and bother/discomfort were 12.3, 19.1 and 6.2, respectively before the treatment. These scores were decreased to 8.9, 9.6 and 4.4, respectively after treatment. All subgroups of Peyronie's Disease Questionnaire scores were significantly improved after treatment (p:0.001, p<0.001, p:0.045, respectively).No adverse events were observed during or after treatment. Conclusion In order to recover the symptoms and signs, new and easily accessible drugs are required for use in the acute period of Peyronie's disease. In this context, treatment with intralesional low dose methylprednisolone in acute phase Peyronie's Disease is a promising and safe treatment option.

show abstract

“…There are many studies about the aetiology and physiopathology of Peyronie's disease in the literature. These studies generally focus on genetic, traumatic, and inflammatory processes 17‐19 . However, regardless of the underlying cause, the inflammatory process that occurs later in the disease forms the basis of plaque formation.…”

Section: Discussionmentioning

confidence: 99%

Intralesional low‐dose methylprednisolone for the treatment of active phase Peyronie’s disease: A single‐centre, preliminary prospective non‐randomised study

Üre

Özen

2020

Int J Clin Pract

View full text Add to dashboard Cite

Aim There are a few types of drugs that can be used in the active phase of Peyronie's disease. Methylprednisolone is a corticosteroid with a strong anti‐inflammatory effect. In this study, we aimed to evaluate the effect of intralesional low‐dose methylprednisolone treatment on patients in the active phase of Peyronie's disease. Patients and Methods Forty‐eight patients suffering from Peyronie's disease active phase symptoms were included in the study. Methylprednisolone was administered intralesionally for 8 weeks, once per week, at a dose of 40 mg. The injection was applied to the plaques, which causes maximum curvature. Patients were evaluated before and after treatment for plaque size, angle of curvature, and erectile dysfunction according to the International Index of Erectile Function‐5 and Peyronie's Disease Questionnaire. Results The mean age of the patients was 61.1 (43‐78) years. The mean duration of the symptoms was 3.4 (0‐9) months. The average plaque size before treatment was 13.6 mm (7.1‐16.8) and after treatment, this value decreased to 10.8 mm (4.3‐14.6) (P: .025). The average scores of Peyronie's Disease Questionnaire elements; symptom severity, penile pain, and bother/discomfort were 12.3, 19.1, and 6.2, respectively, before the treatment. These scores were decreased to 8.9, 9.6, and 4.4, respectively, after treatment. All subgroups of Peyronie's Disease Questionnaire scores were significantly improved after treatment (P: .001, P < .001, P: .045, respectively). No adverse events were observed during or after treatment. Conclusion In order to recover the symptoms and signs, new and easily accessible drugs are required for use in the acute period of Peyronie's disease. In this context, treatment with intralesional low‐dose methylprednisolone in acute phase Peyronie's Disease is a promising and safe treatment option.

show abstract

Levels of serum trace elements in patients with Peyronie

Abstract: The changes in trace element levels are related to the etiopathogenesis of PD. We think that our study is the first from this aspect.

Cited by 11 publications

References 23 publications

New insights into the pathogenesis of Peyronie's disease: A narrative review

New insights into the pathogenesis of Peyronie's disease: A narrative review

Intralesional Low Dose Methylprednisolone for the Treatment of Active Phase Peyronie’s Disease: A Single Center, Preliminary Prospective Non-Randomised Study

Intralesional low‐dose methylprednisolone for the treatment of active phase Peyronie’s disease: A single‐centre, preliminary prospective non‐randomised study

Contact Info

Product

Resources

About